

TERRY JAY SMITH, M.D.

CURRICULUM VITAE

(September 25, 2007)

PERSONAL HISTORY:

Business Address: Harbor-UCLA Medical Center
Division of Molecular Medicine
1124 W. Carson St., Building C-2
Torrance, CA 90502-2006

Work Phone: (310) 222-3691
Fax: (310) 222-6820
e-Mail: tjsmith@ucla.edu

Home address: 2415 Crest Drive
Manhattan Beach, CA 90266

Home Phone: (310) 545-3820

Place of Birth: Kansas City, MO
Citizenship: U.S. Citizen
Marital Status: Married, Linda Polonsky

EDUCATION and TRAINING:

Tulane University, New Orleans, LA	1968-71
University of Missouri School of Medicine, Columbia, MO	Degree: MD 1971-75
The Abraham Lincoln School of Medicine, University of Illinois, Chicago, IL, Internship in Medicine	1975-76
Sinai Hospital, Baltimore, MD Residency in Medicine	1976-77
University of California School of Medicine, San Francisco, CA Fellowship in Biophysics, Cardiovascular Research Institute	1977-78
Columbia University College of Physicians and Surgeons, New York, NY Staff Research Associate, Department of Biochemistry	1978-79
Pritzker School of Medicine, University of Chicago, Chicago, IL Fellow, Department of Medicine, Division of Endocrinology	1979-81

PROFESSIONAL EXPERIENCE:

Present Positions:

Professor of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, CA	1999-
Milly and Steve Liu Scholar in Molecular Medicine Harbor-UCLA Medical Center	1999-
Chief, Division of Molecular Medicine Harbor-UCLA Medical Center, Torrance, CA	1999-
Research Scientist (without compensation) Long Beach VA Medical Center, Long Beach, CA	2000-
Member, Jules Stein Eye Institute, The David Geffen School of Medicine at UCLA, Los Angeles, CA	2000-

Previous Positions Held:

Professor of Medicine Albany Medical College of Union University, Albany, NY	1990-99
Head, Section of Molecular Medicine and Cellular Medicine Albany Medical College of Union University, Albany, NY	1990-99
Professor of Ophthalmology Albany Medical College of Union University, Albany, NY	1995-99
Attending Physician Albany Medical Center Hospital, Albany NY	1995-99
Professor of Biochemistry and Molecular Biology Albany Medical College of Union University, Albany, NY	1991-99
Staff Physician (Endocrinologist) Veterans Administration Medical Center, Albany, NY	1990-99
Associate Professor of Medicine School of Medicine, State University of New York at Buffalo, Buffalo, NY	1986-90
Chief, Section of Endocrinology Veterans Administration Medical Center, Buffalo, NY	1986-90

Visiting Scientist, Center for Neurobiology and Behavior Columbia University, College of Physicians and Surgeons, New York, NY	1986
Associate Professor of Medicine Medical College of Georgia, Augusta, GA	1985-86
Physician/Research Associate, Medical Research Service Veterans Administration Medical Center, Augusta, GA	1983-86
Assistant Professor of Medicine Medical College of Georgia, Augusta, GA	1982-85
Consultant Veterans Administration Medical Center, Augusta, GA	1982-83
Assistant Professor The Rockefeller University, New York, NY	1981-83
Associate Physician The Rockefeller University Hospital, New York, NY	1981-83

PROFESSIONAL ACTIVITIES:

Committee Services:

Departmental:

Member, Department of Medicine Executive Committee, Harbor-UCLA Med. Ctr. 1999-

Institutional:

Member, Investment Committee, Harbor-UCLA Research and Education Institute	2002-
Chair, Research Committee, Harbor-UCLA Research and Education Institute	2001-2006
Member, Board of Directors, Harbor-UCLA Research and Education Institute	2001-2006
Member, Executive Committee, Harbor-UCLA Research and Education Institute	2001-2006
Chair, Subcommittee on Administrative Policies, Harbor-UCLA Research and Education Institute	2001-2006
Member, Finance Committee, Harbor-UCLA Research and Education Institute	1999-
Legislative Assembly, Academic Senate, UCLA	2005-
Med CAP, UCLA Tenure and Promotion Committee	2006-

National Committees:

Member, Department of Veterans Affairs Medical Research Service Merit Review Subcommittee	3/1/02-2/28/05
Abstract Review Committee, The Endocrine Society	2002-
Member, Five Year Research Goals Steering Panel National Eye Institute	1997-
Member, Program Committee, American Thyroid Association	1997-2004

Diabetes and Endocrinology Evaluation Board of the Faculty of 1000 Medicine	2004-
Member, Research Committee, American Thyroid Association	2005-2006

Past Committees:

Member, Quality Assurance Committee, Samuel S. Stratton Department of Veterans Affairs Medical Center, Albany, NY	1994-98
Member, IRB, Albany Medical College, Albany, NY	1995-99
Member, Technology Transfer Committee, Albany Medical College, Albany, NY	1994-99
Member, Research Institutional Biosafety Committee, Wadsworth Center for Laboratories and Research, Department of Health, State of New York, Albany, NY	1992-95
Member, Search Committee, Division of Oncology Head, Albany Medical College, Albany, NY	1991-92
Member, Library Committee, Albany Medical College, Albany, NY	1991-99
Chairman, Research and Development Committee	1992-93
Member, Research and Development Committee, Samuel S. Stratton Department of Veterans Affairs Medical Center, Albany, NY	1991-94
Member, Education Committee, Department of Medicine, Albany Medical College, Albany, NY	1991-99
Member, Committee on Genetics, Albany Medical College, Albany, NY	1991-99
Member, Membership Committee, American Thyroid Association	1988-90
Member, Travel Committee, Veterans Administration Medical Center, Buffalo, NY	1989-90
Chairman, Travel Committee, Veterans Administration Medical Center, Buffalo, NY	1987-89
Member, Research Committee of the Faculty Council, School of Medicine, State University of New York at Buffalo	1987-88
Member, Human Assurance Committee, Medical College of Georgia, Augusta, GA	1984-85
Member, BRSG Committee, Medical College of Georgia, Augusta, GA	1984-85
Member, Ad Hoc Proposal Review Subcommittee, VA Medical Center, Augusta, GA	1983-85
Member, Faculty Senate Medical College of Georgia, Augusta, GA	1983-85

Other Activities:

Course Director, " <i>Innovative Approaches to the Treatment of Graves' Orbitopathy</i> " Columbia University College of Physicians & Surgeons, New York, NY	9/7/01-9/9/01
Course Director, " <i>Graves' Disease International Symposium: New Insights for TAO: From Bench to Bedside</i> " Jules Stein Eye Institute, Los Angeles, CA	11/17/06-11/18/06

Editorial Services:

Editorial Board Member - American Journal of Physiology	1995-98
Reviewer – Endocrinology	1984-
Reviewer – Journal of Clinical Endocrinology and Metabolism	1983-
Reviewer – American Journal of Physiology	1990-
Reviewer – Biochimica et Biophysica Acta	1991-
Reviewer – Journal of Biological Chemistry	1998-

Reviewer – Endocrine Research	1995-
Reviewer – National Science Foundation	1984-
Reviewer – Archives of Internal Medicine	1983-
Reviewer – Acta Endocrinologica	1986-
Reviewer – Journal of Clinical Investigation	1988-
Reviewer – Journal of Molecular and Cellular Cardiology	1990-
Reviewer – Merit Review Board of the Veterans Administration	1987-
Reviewer – Experimental Cell Research	2002-
Reviewer – New England Journal of Medicine	1995-
Reviewer – Clinical Immunology and Immunopathology	1996-
Reviewer – Investigative Ophthalmology & Visual Science	1994-
Reviewer – Proceedings of the National Academy of Sciences (USA)	1994-
Reviewer – Thrombosis and Haemostasis	1992-
Reviewer – Endocrine	2000-
Reviewer – Thyroid	2002-
Reviewer – Metabolism	1998-
Reviewer – Journal of Cellular Physiology	1995-
Reviewer – Journal of Molecular Medicine	1997-
Reviewer – Immunology Letters	2002-
Reviewer – Biochemistry	2004-
Reviewer – National Institutes of Health	1993-
Reviewer – Current Medicinal Chemistry Review	2002-
Reviewer – FEBS Letters	2002-
Reviewer – International Immunology	2003-
Reviewer – Endocrine Society	2003-
Reviewer – American Journal of Ophthalmology	2003-
Reviewer – Journal of Neurosciences	2003-
Reviewer – The Journal of Immunology	2002-
Reviewer – Journal of Leukocyte Biology	2005-
Reviewer – Journal of Cell Science	2005-

Consulting Activities:

Merck Pharmaceuticals	(1997 -)
Wyeth-Ayerst Laboratories	(1996 -)
Research Management Group	(2000 -)

HONORS, SOCIETIES AND SPECIAL AWARDS

Orbit Society	2007
Excellence in Clinical Research Award, Harbor-UCLA Medical Center	2002
Western Association of Physicians	2002
Outstanding Young Physician Award, Univ. of Missouri School of Medicine	1993
American Society for Biochemistry and Molecular Biology	1990
American Federation for Clinical Research	1988
American Thyroid Association	1985-2006
New York Academy of Sciences	1984

Research Career Development Award, Department of Veterans Affairs	1983-86
Sigma XI	1983
The Endocrine Society	1982
Charles D. Tandy Clinical Scholar, Rockefeller University	1981-83
Visiting Fellow, Department of Medicine (Endocrinology), Columbia University College of Physicians and Surgeons, New York, NY	1978-79
University Scholar, Univ. of California School of Medicine, San Francisco, CA	1977-79
Fellow, University of California School of Medicine, San Francisco, CA	1977-78
Student Fellowship, University of Birmingham, U.K.	1975
Beta Beta Beta	1970
Alpha Epsilon Delta	1970
Woodrow Wilson Fellowship Nominee	1970
Phi Eta Sigma	1969

Research Grants and Fellowships Received: (Continuous from NIH and/or VA since 1983)

Title: **Effects of Thyroid Hormone on Glycosaminoglycan Metabolism in Human Skin Fibroblasts**
 PI: Terry J. Smith, M.D.
 Source: BRSG
 Amount: \$3,996
 Duration: Apr 83 - Mar 84
 Status: Approved and Funded (project completed)

Title: **Effects of Thyroid Hormone on Glycosaminoglycan and Na⁺K⁺ ATPase in Fibroblasts**
 PI: Terry J. Smith, M.D.
 Source: Veterans Administration RCDA
 Amount: \$210,456 (includes 100% salary support for PI)
 Duration: July 83 - Jun 86
 Status: Approved and Funded (project completed)

Title: **Effects of Thyroid Hormone on Glycosaminoglycan and Na⁺K⁺ ATPase in Fibroblasts**
 PI: Terry J. Smith, M.D.
 Source: Veterans Administration Merit Review
 Amount: \$67,500
 Duration: Apr 84 - Mar 87
 Status: Approved and Funded (project completed)

Title: **Hormonal Regulation of Hyaluronate Synthesis in Human Skin Fibroblasts**
PI: Terry J. Smith, M.D.
Source: BRSG
Amount: \$27,534
Duration: July 86 - Sept 87
Status: Approved and Funded (project completed)

Title: **Is the Human Fibroblast a Significant Mediator of Thyroid Disease?**
PI: Terry J. Smith, M.D.
Source: Veterans Administration Merit Review
Amount: \$116,003
Duration: Oct 87 - Sept 90
Status: Approved and Funded

Title: **Cellular Biomarkers of Aging (R01 AG07736-02)**
PI: Paul J. Davis, M.D. Co-Investigator: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$454,830
Duration: Apr 88 - Mar 93
Status: Approved and Funded (Project completed)

Title: **Is the Human Fibroblast a Significant Mediator of Thyroid Disease?**
PI: Terry J. Smith, M.D.
Source: Veterans Administration Merit Review
Amount: \$217,600
Duration: Oct 90 - Sept 94
Status: Approved and Funded

Title: **Regulation of Retroocular Connective Tissue
R01EY08976-03**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$520,358
Duration: Dec 1992-Nov 1995
Status: Approved and Funded

Title: **Is the Human Fibroblast a Significant Mediator of Thyroid Disease?**
PI: Terry J. Smith, M.D.
Source: Veterans Administration Merit Review
Amount: \$245,300
Duration: Oct 1994-Sept 1997
Status: Approved and Funded (continuous since 1983)

Title: **Regulation of Retroocular Connective Tissue
RO1 EY-8976-04-08**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$783,052 (Direct costs)
Duration: Dec 1995-Dec 2000
Status: Approved and Funded

Title: **Functional Diversity of Orbital Fibroblasts
RO1EY11708-01-05**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$1,072,228 (Direct costs)
Duration: Apr 1997-Mar 2002
Status: Approved and funded

Title: **Is the Human Fibroblast a Significant Mediator of Thyroid Disease?**
PI: Terry J. Smith, M.D.
Source: Veterans Administration Merit Review
Amount: \$500,000 (Direct costs)
Duration: Mar 1999-Mar 2004
Status: Approved and funded (Project completed)

Title: **Regulation of Retroocular Connective Tissue
2 RO1 EY08976-09**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$ 962,386 (Direct costs)
Duration: Dec 2000 – Nov 2004
Status: Approved and Funded

Title: **Down-Regulation of Bcl-2 in Synovial Fibroblasts Mediated by Peptide
Nucleic Acids**
Co-PI: Terry J. Smith, M.D.
Source: Arthritis Foundation-So. California Chapter
Amount: \$19,000 (Direct Costs)
Duration: 7/1/02 – 06/30/03
Status: Approved and funded (Project Completed)

Title: **Fibroblast Immune Activation in Graves' Disease**
Mentor: Terry J. Smith, M.D.
P.I. Raymond S. Douglas, M.D., Ph.D.
Source: American Thyroid Association
Amount: \$50,000 (Direct Costs)
Duration: 7/1/04 – 6/30/06
Status: Approved and funded (Project Completed)

Title: **Functional Diversity of Orbital Fibroblasts
RO1 EY11708**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$1,456,501 (Direct Costs)
Duration: 4/1/02 – 3/31/07
Status: Approved and funded

Current Funding

Title: **Thyocytes Express Inflammatory Mediators
K23 RR017304**
Mentor: Terry J. Smith, M.D.
P.I. Andrew Gianoukakis, M.D.
Source: National Institutes of Health
Amount: \$625,000 (Direct Costs)
Duration: 7/15/02 – 6/30/07
Status: Approved and funded

Title: **Immune Activation of Fibroblasts
K23 EY016339**
Mentor: Terry J. Smith, M.D.
P.I. Raymond S. Douglas, M.D., Ph.D.
Source: National Institutes of Health
Amount: \$746,000 (Direct Costs)
Duration: 7/1/04 – 6/30/09
Status: Approved and funded

Title: **Immunoglobulin Activation of Fibroblasts
RO1 DK063121-01 and AR063121-01**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$1,670,712 (Direct Costs)
Duration: 7/1/04 – 6/30/09
Status: Approved and funded

Title: **Regulation of Retroocular Connective Tissue
RO1 EY008976-13**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$ 1,250,000 (Direct costs)
Duration: 12/1/04 – 11/30/09
Status: Approved and funded

Title: **Functional Diversity of Orbital Fibroblasts
RO1 EY011708**
PI: Terry J. Smith, M.D.
Source: National Institutes of Health
Amount: \$1,544,490 (Direct Costs)
Duration: 4/1/07 – 3/31/12
Status: Approved and funded

Research Grants Submitted:

None.

PATENTS:

Application Number: 03710635.8
Application Title: “A Novel Therapy for Antibody Mediated Inflammatory Auto-Immune Disorders”

Application Number: US03/00187
Application Title: “A Novel Therapy for Antibody Mediated Inflammatory Auto-Immune Disorders”

Application Number: 10/046,651
Application Title: “Detection of Antibody Mediated Inflammatory Auto-Immune Disorders”

Application Number: 10/038,509
Application Title: “A Novel Therapy for Antibody Mediated Inflammatory Auto-Immune Disorders”

Application Number: 10/140,003
Application Title: “A Novel Therapy for Antibody Mediated Inflammatory Auto-Immune Disorders”

LECTURES AND PRESENTATIONS:

<i>“Management of Thyroid –Associated Ophthalmopathy”</i> Endocrine Society Meeting, Boston, MA	11/03/98
<i>“Molecular Basis for Anti-Inflammatory Therapy in Graves’ Disease”</i> Grand Rounds, Cornell Univeristy Medical School, New York, NY	12/02/98
<i>“The Biochemistry of Inflammation”</i> Merck and Co., West Point, PA	01/18/99
<i>“Molecular Basis for Cyclooxygenase Induction”</i> Merck and Co., West Point, PA	02/11/99

<i>“The Molecular Pathogenesis of Graves’ Ophthalmopathy”</i> Basic Science, Harbor-UCLA Medical Center, Torrance, CA	02/22/99
<i>“Biochemical Basis for Non-Steroidal Anti-Inflammatory Action”</i> Wyeth-Ayerst Laboratories, St. Davids, PA	03/02/99
<i>“Molecular Pathogenesis of Graves’ Ophthalmopathy”</i> Duke University School of Medicine, Durham, NC	03/08/99
<i>“The Regulation of Gene Expression”</i> Union University, Albany, NY	03/22/99
<i>“Thyroid Dysfunction”</i> Veterans Affairs Medical Center, Upstate, NY	04/12/99
<i>“The Mechanisms for NSAID actions in Arthritis”</i> Northeastern Rheumatology Association, Albany, NY	04/16/99
<i>“Cyclooxygenase Pathways”</i> Merck and Co., West Point, PA	04/26/99
<i>“Phenotypic Diversity of Fibroblasts”</i> University of Edinburgh, Scotland	05/03/99
<i>“New Insights Into COX Enzymes: Implications for Clinical Therapy of Rheumatoid Arthritis and Osteoarthritis”</i> Meeting of the Louisiana State Osteoorthopedic Society, New Orleans, LA	05/22/99
<i>“New Insights into the Biology of Cyclooxygenases”</i> New York State Council of Health Systems Pharmacists, Rochester, NY	05/23/99
<i>“Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy: The Putative Role of Cyclooxygenases”</i> Grand Rounds, University of Connecticut, Farmington, CT	06/02/99
<i>“NSAID Therapy in Chronic Arthritis”</i> Grand Rounds, Phelps Hospital, Port Chester, NY	06/08/99
<i>“New Therapies for Old Ills-Selective COX-2 Inhibitors”</i> Westchester New York Medical Society, Westchester, NY	06/08/99
<i>“COX-2 Pathways-Targets for Arthritis Therapy”</i> Mt. Kiskow Medical Society, Mt. Kiskow, NY	06/21/99
<i>“New Therapies for Chronic Inflammation”</i> Western New York Medical Society, Rochester, NY	06/23/99

<i>Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy</i> Grand Rounds, University of Rochester, Rochester, NY	06/24/99
<i>“Clinical and Molecular Aspects of Thyroid-Associated Ophthalmopathy”</i> Meet-the Professor Lecture, Annual Meeting of the American Thyroid Association, Palm Beach, FL	10/01/99
<i>“Putative Role of Prostaglandins in the Pathogenesis of Thyroid-Associated Ophthalmopathy”</i> German Endocrine Society Meeting, Bingen, Germany	11/26/99
<i>“The Molecular Pathogenesis of Graves’ Ophthalmopathy”</i> Grand Rounds, Jules Stein Eye Institute – UCLA, Los Angeles, CA	05/31/00
<i>“The Molecular Pathogenesis of Graves’ Ophthalmopathy”</i> Pacific Northwest Research Institute, Seattle, WA	10/18/00
<i>“Orbital Fibroblasts Exhibit a Novel Phenotype: Potential Basis For the Pathogenesis of TAO”</i> 12 th International Thyroid Congress, Kyoto, Japan	10/21/00
<i>“Pathogenesis of Graves’ Disease”</i> University of Sydney, Australia	11/08/00
<i>“Molecular Insights into Graves Disease Promise Dramatic New Therapies”</i> Grand Rounds, Harbor-UCLA Medical Center, Torrance, CA	11/14/00
<i>“Graves’ Ophthalmopathy”</i> Grand Rounds, Albany Medical College, Albany, NY	03/23/01
<i>“Role of Orbital Fibroblasts in Graves’ Ophthalmopathy”</i> Innovative Approaches to the Treatment of Graves’ Orbitopathy, Columbia University College of Physicians and Surgeons, New York, NY	09/08/01
<i>“Orbital Fibroblasts”</i> Vancouver Orbital Symposium, Vancouver BC, Canada	03/16/02
<i>“Pathogenesis of Graves’ Ophthalmopathy”</i> Endocrine Grand Rounds, UCLA School of Medicine, Los Angeles, CA	03/20/02
<i>“Pathogenesis of Graves’ Ophthalmopathy and its Implications on Autoimmunity”</i> Shanghai Institute of Endocrinology, Shanghai, China	03/27/02

- “Pathogenesis of Graves’ Disease”* 03/29/02
Zhejiang University, Hangzhou, China
- “The Pathogenesis of Graves’ Ophthalmopathy”* 06/04/02
Endocrinology Grand Rounds, Cedars-Sinai Medical Center
Los Angeles, CA
- “Graves Ophthalmopathy”* 09/04/02
Endocrinology Grand Rounds, City of Hope Medical Center
Duarte, CA
- “Cytokines and Graves’ Ophthalmopathy”* 10/03/02
CDA/CSEM Annual Meeting, Vancouver Canada
- “Molecular Pathogenesis of Graves’ Disease”* 12/13/02
Division of Immunology, Johns Hopkins School of Medicine
Baltimore, MD
- “Fibroblasts Diversity Might Explain the Pathogenesis of Graves’
Ophthalmopathy”* 03/27/03
McGill University, Montreal Canada
- “Identification of a Previously Unrecognized Self-antigen in Graves’ Disease”* 03/27/03
2003 McGill University Lecture, McGill University, Montreal Canada
- “The Pathogenesis of Graves’ Ophthalmopathy; some surprises?”* 04/23/03
University of Connecticut, Farmington, CT
- “Molecular Pathogenesis of Graves’ Disease”* 11/06/03
Jules Stein Eye Institute, UCLA, Los Angeles, CA
- “Insights into Pathogenesis of Graves’ Ophthalmopathy”* 11/15/03
Featured Plenary Speaker
American Society for Ophthalmic and Reconstructive Surgery (ASOPRS)
Disneyland Hotel, Anaheim, CA
- “New Insights into Pathogenesis of Graves’ Disease”* 12/01/03
Excellence in Clinical Research Lecture
Harbor-UCLA Medical Center, Torrance, CA
- “The Pathogenesis of Thyroid Associated Ophthalmopathy”* 04/14/04
Endocrine Clinical Conference
Harbor-UCLA Medical Center, Torrance, CA
- “The Pathogenesis of Thyroid Associated Ophthalmopathy”* 04/30/04
Conference on Autoimmunity and Oncology, Ulm, Germany

- “New Concepts in Patho-physiology of Graves’ Orbitopathy and Implication for Management”* 05/22/04
Jules Stein Eye Institute Clinical and Research Seminar
Jules Stein Eye Institute, Los Angeles, CA
- “Antibodies to the IGF1 Receptor, Fibroblasts and Graves’ Disease/Endocrinopathy”* 09/17/04
Course and Workshop on Immuno-endocrinology, Rotterdam, Netherlands
- “Obesity and Diabetes in the U.S.”* 10/04/04
Board of Directors Meeting of the Health Policy Institute
Kansas City, Missouri
- “New Developments in Autoimmune Disease”* and
“The Art (Business) of Obtaining Grants” 10/18/04
(Two Lectures) Los Angeles Biomedical Foundation Meeting at
Harbor-UCLA Medical Center, Torrance, CA
- “The Pathogenesis of Thyroid Associated Ophthalmopathy”* 10/22/04
National Graves’ Disease Foundation,
Patient/Family Conference: “A Bridge to Wellness XII”, Chicago, IL
- “Graves’ Disease”* 11/02/04
Department of Medicine Grand Rounds
Harbor-UCLA Medical Center, Torrance, CA
- “Developing Institutional Vision for Academic Success”* 12/03/04
Leadership Strategic Planning
Health Policy Institute, Kansas City, MO
- “Graves’ Ophthalmopathy: A Fibroblast-Mediated Disease”* 12/07/04
Lung Biology Seminar Series
University of Rochester, New York
- “Graves’ Ophthalmopathy: A Fibroblast-Mediated Disease”* 01/28/05
Department of Pathology Grand Rounds
Harbor-UCLA Medical Center, Torrance, CA
- “Graves’ Disease”* 01/20/06
Department of Pediatrics Clinical Case Conference
Harbor-UCLA Medical Center, Torrance, CA
- “Graves’ Ophthalmopathy: Looking from the Bench to Bedside”* 02/03/06
Invited Plenary Lecture
Western Association of Physicians Meeting, Carmel, CA

- “Thyroid Orbitopathy: A Molecular View”* 04/24/06
Ophthalmology Grand Rounds,
New Jersey Medical School, UMDNJ, Newark, NJ
- “Graves’ Ophthalmopathy: Insights into its Pathogenesis and
New Directions for Therapeutic Intervention”* 04/25/06
Medical Grand Rounds
New Jersey Medical School, UMDNJ, Newark, NJ
- “The Molecular Pathogenesis of Graves’ Ophthalmopathy:
A Disease of Orbital Fibroblasts”* 05/17/06
Ophthalmology Grand Rounds
Case Western Reserve University, Cleveland, OH
- “Controversies in Graves’ Disease: Orbit and Endocrinologic
Issues Facing the Ophthalmologist”* 11/13/06
Joint Meeting of the American Academy of Ophthalmology and
the Asia Pacific Academy of Ophthalmology
Venetian Hotel, Las Vegas, NV
- “State of the Art 2: Role of Fibroblasts and the IGF-1 Receptor in TAO”* 11/18/06
Graves’ Disease International Symposium:
New Insights for TAO: From Bench to Bedside
Jules Stein Eye Institute, Los Angeles, CA
- “A Putative Role for the IGF-1 Receptor in the Pathogenesis of
Graves’ Ophthalmopathy”* 12/12/06
Invited Lecture
King's College London, London, England
- “Novel Common Strategies to Fight Autoimmune Diseases and Cancer”* 01/19/07
Invited Lecture
Los Angeles Biomedical Research Institute Foundation
Rolling Hills, CA
- “The Molecular Pathogenesis of Graves’ Ophthalmopathy”* 04/25/07
Endocrine Grand Rounds
University of California, Irvine Medical Center, Orange, CA
- “Pathogenesis of Graves’ Ophthalmopathy”* 05/02/07
Seminar for the Interdisciplinary Immunology Group at UCLA
Los Angeles, CA

- “Advances in the Molecular Pathogenesis of TAO”* 05/08/07
The Association for Research in Vision and Ophthalmology (ARVO)
Ft. Lauderdale, FL
- “The Molecular Pathogenesis of Graves’ Ophthalmopathy”* 06/14/07
Grand Rounds
University of Michigan, Kellogg Eye Center, Ann Arbor, MI
- “The Molecular Pathogenesis of Graves’ Ophthalmopathy”* 06/14/07
Basic Science
University of Michigan, Kellogg Eye Center, Ann Arbor, MI
- “Graves’ Disease Challenges Ophthalmologists and Endocrinologists”* 06/22/07
Invited Lecture
Department of Ophthalmology, Veterans General Hospital
Taipei, Taiwan
- “The Molecular Pathogenesis of Graves’ Ophthalmopathy”* 06/24/07
Invited Lecture
Chinese Plenary Medical Association
Taipei, Taiwan

RESEARCH PAPERS (PEER REVIEWED)

A. RESEARCH PAPERS (PEER REVIEWED)

1. Kilburn, K.H., Hess, R.A., Thurston, R.J. and Smith, T.J.: Ultrastructural features of osmotic shock in mussel gill cilia. **Journal Ultrastructural Research** 60:34-43, 1977.
2. Smith, T.J. and Edelman, I.S.: The role of sodium transport in thyroid thermogenesis. **Federation Proceedings** 38:2150-2153, 1979.
3. Ramsden, D.B., Smith, T.J., Burr, W.A., Black, E.G., Lee, J.M. and Hoffenberg, R.: Effects of surgical stress and corticotrophin on the peripheral metabolism of thyroid hormones in rabbits. **Journal of Endocrinology** 82:403-408, 1979.
4. Schonberg, M., Smith, T.J., Krichevsky, A. and Bilezikian, J.P.: Glucocorticoids enhance glucose uptake and affect beta-adrenergic responsiveness in muscle cell cultures. **Cell Differentiation** 10:101-107, 1981.
5. Smith, T.J., Horwitz, A.L. and Refetoff, S.: The effect of thyroid hormone on glycosaminoglycan accumulation in human skin fibroblasts. **Endocrinology** 108:2397-2399, 1981.

6. Smith, T.J., Dana, R., Krichevsky, A., Bilezikian, J.P. and Schonberg, M.: Inhibition of β -adrenergic responsiveness in muscle cell cultures by dexamethasone. **Endocrinology** 109:2110-2116, 1981.
7. Eil, C., Fein, H.G., Smith, T.J., Furlanetto, R.W., Bourgeois, M., Stelling, M.W. and Weintraub, B.D.: Nuclear binding of [¹²⁵I]triiodothyronine in dispersed, cultured skin fibroblasts from patients with resistance to thyroid hormone. **Journal of Clinical Endocrinology and Metabolism** 55:502-510, 1982.
8. Smith, T.J., Murata, Y., Horwitz, A.L., Philipson, L. and Refetoff, S.: Regulation of glycosaminoglycan synthesis by thyroid hormone in vitro. **Journal of Clinical Investigation** 70:1066-1073, 1982.
9. Smith, T.J., Drummond, G.S., Kourides, I.A. and Kappas, A.: Thyroid hormone regulation of heme oxidation in liver. **Proceedings of the National Academy of Sciences, U.S.A.** 79:7537-7541, 1982.
10. Refetoff, S., Salazar, A., Smith, T.J. and Scherberg, N.H.: The consequences of inappropriate treatment because of failure to recognize the syndrome of pituitary and peripheral tissue resistance to thyroid hormone. **Metabolism** 32:822-834, 1983.
11. Murata, Y., Refetoff, S., Horwitz, A.L., Smith, T.J.: Hormonal regulation of glycosaminoglycan accumulation in fibroblasts from patients with resistance to thyroid hormone. **Journal of Clinical Endocrinology and Metabolism** 57:1233-1239, 1983.
12. Smith, T.J., Hendry, L.B. and Bransome, Jr., E.D.: Are the stereochemistry and mechanism of action of thyroid hormones predicted by the structure of DNA? **Perspectives in Biology and Medicine** 27:408-416, 1984.
13. Smith, T.J.: Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts: Similar effects of glucocorticoid and thyroid hormones. **Journal of Clinical Investigation** 74:2157-2163, 1984.
14. Smith, T.J.: Glucocorticoid regulation of glycosaminoglycan accumulation in murine fibroblasts. **Endocrine Research** 11:171-179, 1985.
15. Fierro-Benitez, R., Barsano, C.P., Smith, T.J., Seiden, L., Murata, Y. and Eichfeld, J.: Accentuation of gross locomotor activity in the progeny of rats fed a low-iodine diet during and after pregnancy. In: **Frontiers in Thyroidology**, Vol. II. G. Medeiros-Neto and E. Gaitan, Eds. Plenum, New York, 1986. pp.1013-1016.
16. Kline, E.L., Carland, K. and Smith, T.J.: Triiodothyronine repression of imidazole-induced tyrosinase expression in B16 melanoma cells. **Endocrinology** 119:2118-2123, 1986.

17. Smith, T.J., Drummond, G.S. and Kappas, A.: Cobalt-protoporphyrin suppresses thyroid and testicular hormone concentrations in rat serum: A novel action of this synthetic heme analogue. **Pharmacology** 34:9-16, 1987.
18. Davis, R.E. and Smith, T.J.: Thyroid and glucocorticoid hormone regulation of specific protein abundance in cultured human skin fibroblasts. **Endocrine Research** 13:61-67, 1987.
19. Smith, T.J.: n-Butyrate inhibition of hyaluronate synthesis in cultured human fibroblasts. **Journal of Clinical Investigation** 79:1493-1497, 1987.
20. Bahn, R.S., Zeller, J.C. and Smith, T.J.: n-Butyrate increases c-erb A oncogene expression in human colon fibroblasts. **Biochemical Biophysical Research Communications** 150:259-262, 1988.
21. Smith, T.J.: Glucocorticoid regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts: Evidence for a receptor-mediated mechanism involving effects on specific de novo protein synthesis. **Metabolism** 37:179-184, 1988.
22. Smith, T.J. and Kline, E.L.: Multi-hormonal regulation of tyrosinase expression in B16/C3 melanoma cells in culture. In: **Hormones, Cell Biology and Cancer: Perspectives and Potentials**. W.D. Hankins and D. Puett, eds. Alan R. Liss, New York. pp. 241-255, 1988.
23. Kline, E.L., Smith, T.J., Carland, K.A. and Blackmon, B.: Inhibition of imidazole-induced tyrosinase activity by estradiol and estriol in cultured B16/C3 melanoma cells. **Journal of Cellular Physiology** 134:497-502, 1988.
24. Smith, T.J. and Drummond, G.S.: Thyroid hormone regulation of heme synthesis in rat liver. **Endocrinology** 122:1964-1967, 1988.
25. Kline, E.L., Carland, K.A., Warren, Jr., J.T. and Smith, T.J.: Effect of testosterone on imidazole-induced tyrosinase expression in B16 melanoma cell culture. **Cancer Research** 48:3586-3590, 1988.
26. Smith, T.J. and Kline, E.L.: 3,3',5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells. **Biochemical Biophysical Research Communications** 155:1293-1296, 1988.
27. Smith, T.J., Davis, F.B. and Davis, P.J.: Retinoic acid is a modulator of thyroid hormone activation of Ca²⁺-ATPase in the human erythrocyte membrane. **Journal of Biological Chemistry** 264:687-689, 1989.

28. Smith, T.J., Warren, Jr., J.T. and Kline, E.L.: Retinoic acid blockade of imidazole-induced tyrosinase expression in B16 melanoma cultures; similar effects of the active retinoid and triiodothyronine. **Biochemical Biophysical Research Communications** 162:288-293, 1989.
29. Smith, T.J., Bahn, R.S. and Gorman, C.A.: Connective tissue, glycosaminoglycans, and diseases of the thyroid. **Endocrine Reviews** 10:366-391, 1989.
30. Bahn, R.S., Gorman, C.A., Johnson, C.M. and Smith, T.J.: Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. **Journal of Clinical Endocrinology and Metabolism** 69:622-628, 1989.
31. Sirianni, S.R., Mora, M.E., Sands, A.M., Puckhaber, D. and Smith, T.J.: Malignant lymphoma presenting with severe hypercalcemia. **New York State Journal of Medicine** 89:533-535, 1989.
32. Smith, T.J., Bahn, R.S. and Gorman, C.A.: Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: Evidence for differences between retroocular and dermal fibroblasts. **Journal of Clinical Endocrinology and Metabolism** 69:1019-1023, 1989.
33. Bahn, R.S., Smith, T.J. and Gorman, C.A.: The central role of the fibroblast in the pathogenesis of extrathyroidal manifestations of Graves' disease. **Acta Endocrinologica** 121 Supplement 275-81, 1989.
34. Smith, T.J.: Retinoic acid inhibition of hyaluronate synthesis in cultured human skin fibroblasts. **Journal of Clinical Endocrinology and Metabolism** 70:655-660, 1990.
35. Davis, F.B., Smith, T.J., Deziel, M.R., Davis, P.J., and Blas, S.D.: Retinoic acid inhibits calmodulin binding to human erythrocyte membranes and reduces membrane Ca^{2+} -adenosine triphosphatase activity. **Journal of Clinical Investigation** 85:1999-2003, 1990.
36. Smith, T.J.: Neck and thyroid examination. In: **Clinical Methods**. H.K. Walker, D. Hall and J.W. Hurst, Eds. Butterworth Publishers, Boston pp 650-652, 1990.
37. Wang, X.C., Smith, T.J. and Lau, J.T.Y.: Transcriptional regulation of the liver β -galactoside α 2, 6-sialyltransferase by glucocorticoids. **Journal of Biological Chemistry** 265:17849-17853, 1990.
38. Davis, F.B., Smith, T.J., Davis, P.J., Lawrence, W.D., Ryan Jr., A.J., Farrell, M.O. and Blas, S.D.: Sex-dependent inhibition by retinoic acid of thyroid hormone action on rabbit reticulocyte Ca^{2+} ATPase activity. **Biochemical Journal** 273:489-492, 1991.
39. Smith, T.J., Haque, S. and Drummond, G.S.: Induction of heme oxygenase mRNA by cobalt protoporphyrin in rat liver. **Biochimica et Biophysica Acta** 1073:221-224, 1991.

40. Smith, T.J., Bahn, R.S., Gorman, C.A. and Cheavens, M.: Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. **Journal of Clinical Endocrinology and Metabolism** 72:1169-1171, 1991.
41. Smith, T.J., Davis, F.B., Davis, P.J. and Blas, S.D.: Stereochemical requirements for the retinoid blockade of thyroid hormone binding and activation of Ca²⁺-ATPase in human erythrocyte membranes. In: **Progress in Thyroid Research: Proceedings of the 10th International Thyroid Conference** (Gordon, A. and Gross, J., editors) pp. 841-843, 1991.
42. Heufelder, A.E., Smith, T.J., Gorman, C.A. and Bahn, R.S.: Increased induction of HLA-DR by interferon gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. **Journal of Clinical Endocrinology and Metabolism** 73:307-313, 1991.
43. Davis, F.B., Smith, T.J., Davis, P.J. and Blas, S.D.: Structure-activity relationships of retinoids as inhibitors of calmodulin-dependent human erythrocyte Ca²⁺-ATPase activity and calmodulin binding to membranes. **Biochemical Journal** 277:603-606, 1991.
44. Smith, T.J. and Drummond, G.S.: Retinoic acid can enhance the stimulation by thyroid hormone of heme oxygenase in the liver of thyroidectomized rats. **Biochimica et Biophysica Acta** 1075:119-122, 1991.
45. Tzung, S-P., Gaines, K.C., Smith, T.J. and Cohen, S.A.: Isolation and characterization of novel liver-derived immunoinhibitory factor. **Hepatology** 14:888-894, 1991.
46. Spaulding, S.W., Smith, T.J., Hinkle, P.M., Davis, F.B., Kung, M-P. and Roth, J.A.: Studies on the biological activity of triiodothyronine sulfate. **Journal of Clinical Endocrinology and Metabolism** 74:1062-1067, 1992.
47. Smith, T.J., Davis, F.B. and Davis, P.J.: Stereochemical requirements for the modulation of retinoic acid of thyroid hormone activation of Ca²⁺-adenosine triphosphatase and binding at the human erythrocyte membrane. **Biochemical Journal** 284:583-587, 1992.
48. Smith, T.J., Ahmed, A., Hogg, M.G. and Higgins, P.J.: Interferon gamma is an inducer of plasminogen activator inhibitor type-1 in human orbital fibroblasts. **American Journal of Physiology: Cell Physiology** 263:C24-C29, 1992.
49. Shah, S., Lance, P., Smith, T.J., Cohen, S.A., Lau, J.T.Y. and Baumann, H.: n-Butyrate reduces the expression of β -galactoside α 2, 6-sialyltransferase gene in Hep G2 cells. **Journal of Biological Chemistry** 267:10652-10658, 1992.
50. Mulloy, A.L., Smith, T.J. and Stachura, M.E.: Growth hormone and prolactin synthesis and release following treatment of hypothyroid rats with thyroxine and/or retinoic acid. **Hormone and Metabolic Research** 24:466-470, 1992.

51. Heufelder, A.E., Bahn, R.S. and Smith, T.J.: Regulation by glucocorticoids of interferon gamma-induced HLA-DR antigen expression in cultured human orbital fibroblasts. **Clinical Endocrinology** 37:59-63, 1992.
52. Higgins, P.J. and Smith, T.J.: Pleiotropic action of interferon gamma in human orbital fibroblasts. **Biochimica et Biophysica Acta** 1181:23-30, 1993.
53. Smith, T.J. and Higgins, P.J.: Interferon gamma regulation of de novo protein synthesis in human dermal fibroblasts in culture is anatomic site-dependent. **Journal of Investigative Dermatology** 100:288-292, 1993.
54. Smith, T.J. and Higgins, P.J.: Bidimensional gel electrophoretic analysis of protein synthesis and response to interferon gamma in human dermal fibroblasts. **Biochimica et Biophysica Acta** 1181:300-306, 1993.
55. Smith, T.J., Kottke, R.J., Lum, H. and Andersen, T.T.: Human orbital fibroblasts in culture bind and respond to endothelin. **American Journal of Physiology: Cell Physiology** 265:C138-C142, 1993.
56. Smith, T.J., Davis, F.B., Davis, P.J., Ramsden, D.B. and Schoenl, M.: Retinoic acid displacement of thyroxine binding from human transthyretin. **Biochimica et Biophysica Acta** 1199:76-80, 1994.
57. Smith, T.J., Wang, H.-S., Hogg, M.G., Henrikson, R.C., Keese, C.R. and Giaever, I.: Prostaglandin E₂ elicits a morphological change in cultured orbital fibroblasts from patients with Graves' ophthalmopathy. **Proceedings of the National Academy of Sciences USA** 91:5094-5098, 1994.
58. Henrikson, R.C. and Smith, T.J.: Ultrastructure of cultured human orbital fibroblasts. **Cell and Tissue Research** 278:629- 631, 1994.
59. Smith, T.J., Wang, H.-S. and Evans, C.H.: Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. **American Journal of Physiology: Cell Physiology** 268:C382-C388, 1995.
60. Qiao, R.-L., Wang, H.-S., Yan, W., Odekon, L.E., del Vecchio, P., Smith, T.J. and Malik, A.B.: Hyaluronan in extracellular matrix is a determinant of endothelial barrier. **American Journal of Physiology: Cell Physiology** 269:C103-C109, 1995.
61. Hogg, M.G., Evans, C.H. and Smith, T.J.: Leukoregulin induces plasminogen activator inhibitor type-1 in human orbital fibroblasts. **American Journal of Physiology: Cell Physiology** 269:C359-C366, 1995.
62. Cao, H., Hogg, M.G., Martino, L.J. and Smith, T.J.: Transforming growth factor- β induces plasminogen activator inhibitor type-1 in cultured human orbital fibroblasts. **Investigative Ophthalmology and Visual Science** 36:1411-1419, 1995.

63. Berenson, C.S. and Smith, T.J.: Human orbital fibroblasts in culture express ganglioside profiles distinct from those in dermal fibroblasts. **Journal of Clinical Endocrinology and Metabolism** 80:2668-2674, 1995.
64. Smith, T.J., Sempowski, G.D., Wang, H.-S., Del Vecchio, P.J., Lippe, S.D., and Phipps, R.P.: Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. **Journal of Clinical Endocrinology and Metabolism** 80:2620-2625, 1995.
65. Wang, H.-S., Keese, C.R., Giaever, I. and Smith, T.J.: Prostaglandin E₂ alters human orbital fibroblast shape through a mechanism involving the generation of cyclic adenosine monophosphate. **Journal of Clinical Endocrinology and Metabolism** 80:3553-3560, 1995.
66. Rosenberg, D.W., Drummond, G.S. and Smith, T.J.: Depletion of cytochrome P-450 by thyroid hormone and cobalt-protoporphyrin IX in rat liver: Evidence that susceptibility varies among forms of the heme protein. **Pharmacology** 51:254-262, 1995.
67. Drummond, G.S., Smith, T.J. and Kappas, A.: Effects of a series of metalloporphyrins on adrenal, testicular and thyroid function in rats. **Pharmacology** 52:178-186, 1996.
68. Smith, T.J., Piscatelli, J.J., Andersen, V., Corasanti, J.G., Wang, H.-S. and Lance, M.P.: n-Butyrate induces plasminogen activator inhibitor type-1 mRNA in cultured Hep G2 cells. **Hepatology** 23:866-871, 1996.
69. Sorisky, A., Pardasani, D., Gagnon, A. and Smith, T.J.: Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. **Journal of Clinical Endocrinology and Metabolism** 81:3428-3431, 1996.
70. Wang, H.-S., Cao, H.J., Winn, V.D., Rezanka, L.J., Frobert, Y., Evans, C.H., Sciaky, D., Young, D.A. and Smith, T.J.: Leukoregulin induction of prostaglandin endoperoxide H synthase-2 in human orbital fibroblasts: an *in vitro* model for connective tissue inflammation. **Journal of Biological Chemistry** 271:22718-22728, 1996.
71. Smith, T.J.: The putative role of cytokine-orbital fibroblast interactions in the pathogenesis of Graves' ophthalmopathy. **Orbit** 15:137-146, 1996.
72. Smith, R.S., Smith, T.J., Blieden, T.M. and Phipps, R.P.: Fibroblasts as sentinel cells: Synthesis of chemokines and regulation of inflammation. **American Journal of Pathology** 151:317-322, 1997.
73. Smith, T.J., Sempowski, G.D., Berenson, C.S., Cao, H.J., Wang, H.-S. and Phipps, R.P.: Human thyroid fibroblasts exhibit a distinctive phenotype in culture: Characteristic ganglioside profile and functional CD40 expression. **Endocrinology** 138:5576-5588, 1997.

74. Smith, T.J.: Cyclooxygenases as the principal targets for the actions of non-steroidal anti-inflammatory drugs. **Rheumatic Disease Clinics of North America** 24:501-523, 1998.
75. Sempowski G.D., Rozenblit, J., Smith, T.J. and Phipps, R.P.: Human orbital fibroblasts are activated through CD40 to induce pro-inflammatory cytokine production. **American Journal of Physiology: Cell Physiology** 274:C707-714, 1998.
76. Zhang, Y., Cao, H.J., Graf, B., Meekins, H., Smith, T.J. and Phipps, R.P.: Cutting edge: CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E₂ production in human lung fibroblasts. **The Journal of Immunology** 160:1053-1058, 1998.
77. Young, D.A., Evans, C.H. and Smith, T.J.: Leukoregulin induction of protein expression in human orbital fibroblasts: Evidence for anatomical-site-restricted cytokine-target cell interactions. **Proceedings of the National Academy of Sciences USA** 95:8904-8909, 1998.
78. Spicer, A.P., Kaback, L.A., Smith, T.J. and Seldin, M.F.: Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. **Journal of Biological Chemistry** 273:25117-25124, 1998.
79. Cao, H.J., Wang, H.-S., Zhang, Y., Lin, H.-Y., Phipps, R.P. and Smith, T.J.: Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: Insights into potential pathogenic mechanisms of thyroid associated ophthalmopathy. **Journal of Biological Chemistry** 273:29615-29625, 1998.
80. Kim, E.C., Zhu, Y., Andersen, V., Sciaky, D., Cao, H.J., Meekins, H., Smith, T.J. and Lance, P. Cytokine-mediated prostaglandin E₂ expression in human colonic fibroblasts. **American Journal of Physiology: Cell Physiology** 275:C988-C994, 1998.
81. Reddy, L.M., Wang, H.-S., Keese, C.R., Giaever, I. and Smith, T.J.: Assessment of the rapid changes associated with elevated cAMP levels in cultured orbital fibroblasts. **Experimental Cell Research** 245:360-367, 1998.
82. Mack, W.P., Stasior, G.O., Cao, H.J., Stasior, O.G. and Smith, T.J.: The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves' ophthalmopathy. **Ophthalmic Plastic and Reconstructive Surgery** 15:260-271, 1999.
83. Smith, T.J.: The putative role of prostaglandin endoperoxide H synthase-2 in the pathogenesis of thyroid-associated ophthalmopathy. **Experimental and Clinical Endocrinology & Diabetes** 107:S160-S163, 1999.

84. Smith, T.J., Jennings, T.A., Sciaky, D. and Cao, H.J.: Prostaglandin endoperoxide H synthase-2 expression in human thyroid epithelium: evidence for constitutive expression *in vivo* and in cultured KAT-50 cells. **Journal of Biological Chemistry** 274:15622-15632, 1999.
85. Smith, T.J. and Parikh, S.J.: HMC-1 mast cells activate human orbital fibroblasts in co-culture: Evidence for up-regulation of prostaglandin E₂ and hyaluronan synthesis. **Endocrinology** 140:3518-3525, 1999.
86. Smith, T.J., Sciaky, D., Phipps, R.P. and Jennings, T.A.: CD40 expression in human thyroid tissue: Evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. **Thyroid** 9:749-755, 1999.
87. Kaback, L.A and Smith, T.J.: Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1 β in human orbital fibroblasts: Potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. **Journal of Clinical Endocrinology and Metabolism** 84:4079-4084, 1999.
88. Cao, H.J. and Smith, T.J.: Leukoregulin up-regulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. **American Journal of Physiology: Cell Physiology** 277:C1075-C1085, 1999.
89. Sciaky, D., Brazer, W., Center, D.M., Cruikshank, W.W. and Smith, T.J.: Cultured human fibroblasts express constitutive IL-16 mRNA: Cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. **The Journal of Immunology** 164(7):3806-3814, 2000.
90. Bell, A., Gagnon, A., Grunder, L., Parikh, S.J., Smith, T.J., and Sorisky, A.: Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. **American Journal of Physiology: Cell Physiology** 279:C335-C340, 2000.
91. Smith, T.J. Orbital fibroblasts exhibit a novel phenotype: potential basis for the pathogenesis of TAO. In: **Progress in Thyroid Associated Ophthalmopathy**. pp 22-28, 2000.
92. Padilla, J., Kaur, K., Cao, H.J., Smith, T.J., and Phipps, R.P.: Peroxisome proliferator activator receptor- γ agonist and 15-deoxy $\Delta^{12,14,12,14}$ -PGJ₂ induce apoptosis in normal and malignant B-lineage cells. **The Journal of Immunology** 165:6941-6948, 2000.
93. Gianoukakis, A.G., Cao, H.J., Jennings, T.A. and Smith, T.J.: Prostaglandin endoperoxide H synthase expression in cultured human thyroid epithelial cells. **American Journal of Physiology: Cell Physiology** 280:C701-C708, 2001.

94. Kaufman, J., Graf, B.A., Leung, E.C., Pollock, S.J., Koumas, L., Reddy, S.Y., Blieden, T.M., Smith, T.J., and Phipps, R.P.: Fibroblasts as sentinel cells: role of the CD40-CD40 ligand system in fibroblast activation and lung inflammation and fibrosis. **Chest** 120:53S-55S, 2001.
95. Smith, T.J. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: Potential basis for the pathogenesis of thyroid-associated ophthalmopathy. **Thyroid** 12:197-203, 2002.
96. Smith, T.J., Koumas, L., Gagnon, A., Bell, A., Sempowski, G.D., Phipps, R.P., and Sorisky, A.: Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. **Journal of Clinical Endocrinology and Metabolism** 87:385-392, 2002.
97. Kazim, M., Goldberg, R.A. and Smith, T.J.: Insights into the pathogenesis of thyroid associated orbitopathy: Evolving rationale for therapy. **Archives of Ophthalmology** 120:380-386, 2002.
98. Koumas, L., Smith, T.J., and Phipps, R.P.: Fibroblast subsets in the human orbit: Thy-1⁺ and Thy-1⁻ subpopulations exhibit distinct phenotypes. **European Journal of Immunology** 32:477-485, 2002.
99. Han, R., Tsui, S., and Smith, T.J.: Up-regulation of prostaglandin E₂ synthesis by interleukin-1 β in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent PGE₂ synthase expression. **Journal of Biological Chemistry** 277:16355-16364, 2002.
100. Pritchard, J., Horst, N., Cruikshank, W., and Smith, T.J.: Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. **The Journal of Immunology** 168:942-950, 2002.
101. Han, R. and Smith, T.J.: Cytoplasmic prostaglandin E₂ synthase is dominantly expressed in cultured KAT-50 thyrocytes, cells that express constitutive prostaglandin-endoperoxide H synthase-2. **Journal of Biological Chemistry** 277:36897-36903, 2002.
102. Smith, T.J.: Fibroblast biology in thyroid diseases. **Current Opinion in Endocrinology & Diabetes** 9:393-400, 2002.
103. Gianoukakis, A.G., Martino, L.J., Horst, N., Cruikshank, W.W., and Smith, T.J.: Cytokine-induced lymphocyte chemoattraction from cultured human thyrocytes: evidence for IL-16 and RANTES expression. **Endocrinology** 144:2856-2864, 2003.
104. Cao, H.J., Han, R., and Smith, T.J.: Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. **American Journal of Physiology: Cell Physiology** 284:C1429-C1437, 2003.

105. Pritchard, J., Han, R., Horst, N., Cruikshank, W.W., and Smith T.J. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the IGF-1 receptor pathway. **The Journal of Immunology** 170:6348-6354, 2003.
106. Koumas, L., Smith, T.J., Feldon, S., Blumberg, N., and Phipps, R.P. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. **American Journal of Pathology** 163:1291-1300, 2003.
107. Smith, T.J. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. **Autoimmunity** 36:409-415, 2003.
108. Smith, T.J.: Unique properties of orbital connective tissue underlie its involvement in Graves' disease. **Minerva Endocrinologica** 28:213-222, 2003.
109. Prabhakar, B.S., Bahn, R.S., and Smith, T.J.: Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. **Endocrine Reviews** 24:802-835, 2003.
110. Gianoukakis, A.G. and Smith, T.J.: The role of cytokines in the pathogenesis of endocrine disease. **Canadian Journal of Diabetes** 28:30-42, 2004.
111. Smith, T.J.: Novel aspects of orbital fibroblast pathology. **Journal of Endocrinological Investigation** 27:246-253, 2004.
112. Turner, C.K., Blieden, T.M., Smith, T.J., Feldon, S.E., Foster, D.C., Sime, P.J., and Phipps, R.P.: A novel ELISpot method for adherent cells. **Journal of Immunological Methods** 291:63-70, 2004.
113. Pritchard, J., Tsui, S., Horst, N., Cruikshank, W.W., and Smith, T.J.: Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with immunoglobulins against the IGF-1 receptor. **The Journal of Immunology** 173:3564-3569, 2004.
114. Smith, T.J. and Hoa, N.: Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, IGF-1 receptor. **Journal of Clinical Endocrinology and Metabolism** 89:5076-5080, 2004.
115. Baglolle, C.J., Reddy, S.Y., Pollock, S.J., Feldon, S.E., Sime, P.J., Smith, T.J., and Phipps, R.P.: Isolation and phenotypic characterization of lung fibroblasts. **Methods in Molecular Medicine** 117:115-127, 2005.
116. Levin, F., Kazim, M., Smith, T.J., and Marcovici, E.: Rosiglitazone-induced proptosis. **Archives of Ophthalmology** 123:119-121, 2005

117. Han, R. and Smith, T.J.: Induction by IL-1 β of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: Modulation of gene promoter activity by IL-4 and interferon γ . **The Journal of Immunology** 174:3072-3079, 2005.
118. Chen, B., Tsui, S., and Smith, T.J.: IL-1 β induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotype attribute relevant to thyroid-associated ophthalmopathy. **The Journal of Immunology** 175:1310-1319, 2005.
119. Smith, T.J. Insights into the role of fibroblasts in human autoimmune diseases. **Clinical and Experimental Immunology** 141:388-397, 2005.
120. Han, R. and Smith, T.J.: T helper type 1 and type 2 cytokines exert divergent influence on the induction of PGE₂ and hyaluronan synthesis by IL-1 β in orbital fibroblasts: Implications for the pathogenesis of thyroid-associated ophthalmopathy. **Endocrinology** 147:13-19, 2006.
121. Shih, M.-J., Liao, S.-L., Kuo, K.-T., Smith, T.J., and Chuang, L.-M. Molecular pathology of Müller's muscle in Graves' ophthalmopathy. **Journal of Clinical Endocrinology and Metabolism** 91:1159-1167, 2006.
122. Gianoukakis, A.G., Douglas, R.S., King, C.S., Cruikshank, W.W., and Smith, T.J.: IgG from patients with Graves' disease induces IL-16 and RANTES expression in cultured human thyrocytes: A putative mechanism for T cell infiltration of the thyroid in autoimmune disease. **Endocrinology** 147:1941-1949, 2006.
123. Gilbert, J.A., Gianoukakis, A.G., Salehi, S., Moorhead, J., Rao, P.V., Khan, M.Z., McGregor, A.M., Smith, T.J., and Banga, J.P.: Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. **The Journal of Immunology** 176:5084-5092, 2006.
124. Antunes, T.T., Gagnon, A., Chen, B., Pacini, F., Smith, T.J., and Sorisky, A.: Interleukin-6 release from human abdominal adipose cells is regulated by thyroid stimulating hormone: effect of adipocyte differentiation and anatomic depot. **American Journal of Physiology – Endocrinology and Metabolism** 290:E1140-E1144, 2006.
125. Chen, B., Tsui, S., Boeglin, W.E., Douglas, R.S., Brash, A.R., and Smith, T.J.: IL-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves' disease: Evidence for anatomic site-selective action of T_H2 cytokines. **Journal of Biological Chemistry** 281:18296-18306, 2006.
126. Baglolle, C.J., Ray, D.M., Bernstein, S.H., Feldon, S.E., Smith, T.J., Sime, P.J., and Phipps, R.P.: More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. **Immunological Investigations** 35:297-325, 2006.

127. Gianoukakis, A.G., Jennings, T.A., King, C.S., Sheehan, C.E., Hoa, N., Heldin, P. and Smith, T.J.: Hyaluronan accumulation in thyroid tissue: Evidence for contributions from epithelial cells and fibroblasts. **Endocrinology** 148:54-62, 2007.
128. Douglas, R.S., Gianoukakis, A.G., Goldberg, R.A., Kamat, S., and Smith, T.J.: Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes. **Clinical and Experimental Immunology** 148:64-71, 2007.
129. Douglas, R.S., Gianoukakis, A.G., Kamat, S., and Smith, T.J.: Aberrant expression of the IGF-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. **The Journal of Immunology** 178:3281-3287, 2007.
130. Smith, T.J.: Editorial: B cell depletion in Graves' disease: The right answer to the wrong question? **Journal of Clinical Endocrinology and Metabolism** 92:1620-1622, 2007.
131. Smith, T.: Editorial: Is a common therapy for autoimmune disease possible? **Future Rheumatology** 2:333-335, 2007.
132. Han, R., Chen, B., and Smith, T.J.: Janus kinase 2 dampens the induction by IL-1 β of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts: evidence for divergent influence on the PGE₂ biosynthetic pathway. **The Journal of Immunology** (In press, 2007)

B. Research Papers – Peer Reviewed (In Press)

1. Smith, T.J. and Henrickson, R.C.: The orbital fibroblast phenotype: an example of human fibroblast diversity. **Histology and Histopathology** (In press, 2007).
2. Smith, T.J.: The diversity of human fibroblasts: Implications to function and disease. **FASEB J.** (In press, 2007).

C. Research Papers – Peer Reviewed (Submitted)

1. Tsui, S., Chen, B., and Smith, T.J.: Human fibroblast UDP glucose dehydrogenase is expressed and regulated in a tissue specific manner: implications for the pathogenesis of thyroid-associated ophthalmopathy. **Journal of Biological Chemistry** (in revision).
2. Douglas, R.S., Naik V., Kamat, S., Pollock, S., Phipps, R.P., Gianoukakis, A.G., and Smith, T.J.: Predisposition to thyroid-associated ophthalmopathy: over-expression of IGF-1 receptor and CD40 and absence of hepatocyte growth factor production by disease-derived orbital fibroblast subsets. (Submitted)

3. Tsui, S., Hoa, N., Press, C.D., Cruikshank, W.W., Sinha Hikim, A., and Smith, T.J.: Cellular redistribution of IGF-1 receptor is provoked in orbital fibroblasts from patients with Graves' disease by IGF-1 and their circulating IgG. (Submitted).
4. Naik, V., Khadavi, N., Naik, M.N., Goldberg, R.A., Tsirbas, A., Smith, T.J., and Douglas, R.S.: Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. (Submitted).
5. Smith, T.J., Tsai, C.C., Shih, M.-J., Tsui, S., Chen, B., Han, R., Naik, V., King, C.S., Kamat, S., Goldberg, R.A., Phipps, R.P., Douglas, R.S., and Gianoukakis, A.G.: Unique attributes of orbital fibroblasts coupled with generalized alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. (Submitted).
6. Gianoukakis, A.G. and Smith, T.J.: Cytokines, Graves' disease and thyroid-associated ophthalmopathy. (Submitted).
7. Lehmann, G.M., Feldon, S.E., Smith, T.J., and Phipps, R.P.: Immune mechanisms in thyroid eye disease. (Submitted).
8. Hoberg, M., Rudert, M., Tsui, S., Pap, T., Angres, B., Smith, T.J., Cruikshank, W.W., Gay, S., and Aicher, W.K.: Attachment to laminin-1 potentiates the TGF- β induced expression of IL-16 in synovial fibroblasts from rheumatoid arthritis patients in absence of IL-1 β . (Submitted).

RESEARCH PAPERS (NON-PEER REVIEWED)

D. Research Papers – Non-Peer Reviewed

1. Simon, L.S. and Smith, T.J.: NSAID mechanism of actions, efficacy, and relative safety. **Postgraduate Medicine** 103 (Supplement):12-16, 1998.

E. Research Papers – Non-Peer Reviewed (In Press)

None.

F. Research Papers – Non-Peer Reviewed (Submitted)

None.

CHAPTERS

1. Smith, T.J.: Neck and thyroid examination. In *Clinical Methods*. H.K. Walker, D. Hall and J.W. Hurst, Eds. Butterworths Publishers, Boston pp 650-652, 1990.
2. Smith, T.J.: Connective tissue in hyperthyroidism. In *The Thyroid*. L.E. Braverman and R.D. Utiger, Eds. J.B. Lippincott Company, Philadelphia pp 734-743, 1991.

3. Smith, T.J.: Connective tissue in hypothyroidism. In *The Thyroid*. L.E. Braverman and R.D. Utiger, Eds. J.B. Lippincott Company, Philadelphia pp 989-992, 1991.
4. Smith, T.J.: Pretibial myxedema and acropachy. In *The Thyroid*. L.E. Braverman and R.D. Utiger, Eds. J.B. Lippincott Company, Philadelphia pp 676-681, 1991.
5. Smith, T.J.: Connective tissue in hyperthyroidism. In *The Thyroid*. L.E. Braverman and R.D. Utiger, Eds. J.B. Lippincott Company, Philadelphia pp 598-606, 1996.
6. Smith, T.J.: Connective tissue in hypothyroidism. In *The Thyroid*. L.E. Braverman and R.D. Utiger, Eds. J.B. Lippincott Company, Philadelphia pp 796-798, 1996.
7. Smith, T.J.: Graves' dermatopathy. In *Endocrine Update: Graves' Disease*. B. Rapoport and S. McLachlan, Eds. Kluwer Academic Publishers, Norwell, MA pp 289-300, 2000.
8. Smith, T.J.: Participation of orbital fibroblasts in the inflammation of Graves' ophthalmopathy. In *Endocrine Update: Thyroid Eye Disease*. R.S. Bahn, Ed. Kluwer Academic Publishers, Boston, MA pp 83-98, 2001.
9. Smith, T.J.: Role of orbital fat in thyroid-associated ophthalmopathy. In *Graves' Associated Orbital Disease*. J.J. Dutton and B.G. Haik, Ed. Marcel Dekker, Inc. Publishers, New York, NY pp 215-221, 2002.
10. Smith, T.J.: Phenotypic attributes of orbital fibroblasts underlie their susceptibility in Graves' disease. In *Orbital Disease: Present Status and Future Challenges*. J. Rootman, Ed. Taylor&Francis, Boca Raton, FL pp 169-181, 2005.
11. Baglole, C.J., Reddy, S.Y., Pollock, S.J., Feldon S.E., Sime, P.J., Smith, T.J., and Phipps, R.P.: Isolation and phenotypic characterization of lung fibroblasts. In *Methods in Molecular Medicine, Vol. 117: Fibrosis Research: Methods and Protocols*. J. Varga, D. Brenner, and S. Phan, Eds. Humana Press, Totowa, NJ pp 115-127, 2005.
12. Baglole, C.J., Smith, T.J., Foster, D., Sime, P.J., Feldon, S., and Phipps, R.P.: Functional assessment of fibroblast heterogeneity by the cell-surface glycoprotein Thy-1. In *Tissue Repair, Contraction and the Myofibroblast*. C. Chaponnier, A. Desmouliere, and G. Gabbiani, Eds. Springer Science+Business Media, Berlin, Germany, pp 32-39, 2006.

CHAPTERS (IN PRESS)

1. Douglas, R.S. and Smith, T.J.: Thyroid Orbitopathy: New Immunologic Concepts and Future Implications. In *Essentials in Ophthalmology - Oculoplastics and Orbit*. Guthoff R. and Katowitz J., Eds. Springer-Verlag, Berlin (In Press, 2007).

2. Smith, T.J. and Douglas, R.S.: Pathophysiology of Graves' Orbitopathy. In *Albert and Jakobiec's Principles and Practice of Ophthalmology, 3rd edition*. D. Albert, J. Miller, D. Azar and B. Blodi, Eds. Saunders, Philadelphia (In press, 2008).

LETTERS TO THE EDITOR

None.

REVIEWS

None.

EDITORIALS

None.

PAPERS IN PREPARATION (RESEARCH COMPLETED)

None.

ABSTRACTS (Selected)

1. Kilburn, K.H., Hess, R.A., Thurston, R.J. and Smith, T.J.: Reversible inhibition of ciliary beating by osmotic shock. **Journal of Cell Biology** 67:210, 1975.
2. Schonberg, M., Smith, T.J., Krichevsky, A. and Bilezikian, J.P.: Glucocorticoids enhance glucose uptake and affect Beta-adrenergic responsiveness in muscle cell culture. **Federation Proceedings** 39:819, 1980.
3. Smith, T.J., Dana, R., Krichevsky, A., Bilezikian, J.P. and Schonberg, M.: Dexamethasone inhibits fusion, cyclic AMP accumulation and Beta-adrenergic receptors in muscle cells in vitro. **Endocrinology Supplement** 108:265, 1981.
4. Schonberg, M., Krichevsky, A., Smith, T.J. and Bilezikian, J.P.: Beta-adrenergic dependent accumulation of deoxyglucose uptake in muscle cell cultures. **Advances in Nucleotide Research** 14:688, 1980.
5. Salazar, A., Refetoff S., Smith, T.J., Scherberg, N.H., Al-Sadir, J. and Kaplan, E.L.: Studies on a new case of resistance to the action of thyroid hormone. **Endocrinology Supplement** 108:193, 1981.

6. Smith, T.J., Horwitz, A. and Refetoff, S.: The effects of thyroid hormone on glycosaminoglycan accumulation. **Endocrinology Supplement** 108:265, 1981.
7. Smith, T.J., Philipson, L., Horwitz, A. and Refetoff, S.: Thyroid hormone inhibits glycosaminoglycan accumulation in human fibroblasts. **Annales d'endocrinologie** 42:17A, 1981.
8. Eil, C., Fein, H., Smith, T., Furlanetto, R., Bourgeois, M. and Weintraub, B.D.: Nuclear binding of $^{125}\text{I-T}_3$ in intact fibroblasts from patients with peripheral thyroid hormone resistance (PTHR). **Program of the 57th Annual Meeting of the American Thyroid Association**, Minneapolis, MN, 1981, T₂.
9. Nakamura, H., Smith, T.J., Refetoff, S., Horwitz, A. and DeGroot, L.J.: T₃ effects on phosphorylation of endogenous proteins in rat liver cytosol and cultured human skin fibroblasts. **Program of 57th Annual Meeting of the American Thyroid Association**, Minneapolis, MN, 1981, T₁₄.
10. Murata, Y., Smith, T.J., Horwitz, A.L. and Refetoff, S.: Possible abnormality in glycosaminoglycan synthesis in fibroblasts from patients with peripheral resistance to thyroid hormone. **Endocrinology Supplement** 110:218, 1982.
11. Carland, K., Smith, T.J. and Kline, E.L.: Effects of iodothyronine derivatives on imidazole induced tyrosinase in B16 melanoma cell cultures. **Program of the Eastern Branch of the American Society of Microbiology Annual Meeting**, Myrtle Beach, SC, October 1983.
12. Hendry, L.B., Smith, T.J. and Bransome, E.D., Jr.: Stereochemical complementarity of thyroid hormones and DNA: A rationale for hormonal activity, function and metabolism. **Clinical Research** 31:835A, 1983.
13. Smith, T.J., Murata, Y., Horwitz, A.L., Philipson, L. and Refetoff, S.: Regulation of glycosaminoglycan synthesis by thyroid hormone in vitro. In: **Year Book of Endocrinology** 1984.
14. Hendry, L.B., Smith, T.J. and Bransome, E.D., Jr.: Stereochemical complementarity of thyroid hormones and DNA: Evidence that triiodothyronine can interact directly and stereospecifically with DNA. **7th International Congress of Endocrinology**, 1984 (Abstract No. 988, page 74).
15. Smith, T.J.: Dexamethasone and triiodothyronine inhibit glycosaminoglycan synthesis through different pathways. **7th International Congress of Endocrinology**, 1984 (Abstract No. 2458, page 1489).

16. Fierro-Benitez, R., Barsano, C.P., Smith, T.J., Seiden, L. Murata, Y. and Eichfeld, J.: Accentuation of gross locomotor activity in the progeny of rats fed a low-iodine diet (LID) during and after pregnancy. **Program of the 9th International Thyroid Congress**, Sept. 1985.
17. Bahn, R. and Smith, T.J.: The effect of n-Butyrate on [³H]glycosaminoglycan synthesis in human fibroblasts. **Clinical Research** 36:381A, 1988.
18. Smith, T., Bahn, R. and Gorman, C.: Evidence for body regional differences in the response to thyroid and glucocorticoid hormones in human fibroblasts. **8th International Congress of Endocrinology**, Kyoto, Japan, 1988.
19. Bahn, R., Gorman, C. and Smith, T.: n-Butyrate inhibits glycosaminoglycan (GAG) synthesis by retroocular, pretibia and abdominal fibroblasts from patients with Graves' disease. **8th International Congress of Endocrinology**, Kyoto, Japan, 1988.
20. Spaulding, S.W., Hinkle, P.M., Smith, T.J., Davis, F.B. and Roth, J.: Thyromimetic activity of T₃SO₄ in several thyroid hormone responsive mammalian systems in vitro. **8th International Congress of Endocrinology**, Kyoto, Japan, 1988.
21. Bahn, R.S., Smith, T.J. and Gorman, C.A.: Fibroblasts from various anatomic sites respond differently to triiodothyronine and dexamethasone. **Program of the Meeting of the American Thyroid Association**, Sept. 28-31, 1988.
22. Spaulding, S.W., Hinkle, P.M., Smith, T.J., Davis, F.B. and Roth, J.: Thyromimetic activity of T₃AO₄ in several thyroid hormone responsive mammalian systems in vitro. **Proceedings of the International Symposium on Graves' Disease**, 1988.
23. Smith, T.J., Davis, F.B., Davis, P.J.: Retinoic acid modulates thyroid hormone activation of human red blood cell membrane Ca²⁺-ATPase in vitro. **Program of the American Society for Biochemistry and Molecular Biology**, San Francisco, CA. **Journal of Cell Biology** 107:483A, 1989.
24. Walters, J.R.F. and Smith, T.J.: Intestinal Calcium²⁺ transport in hyperthyroid and hypothyroid rats. **Clinical Research** 37:365A, 1989.
25. Bahn, R.S., Gorman, C.A., Garrity, J.A. and Smith, T.J.: Immunoblot analyses of retroocular and pretibial fibroblasts: Presence of autoantibodies to a 23kD protein in Graves' sera. **Endocrinology Supplement** 124:181, 1989.
26. Davis, F.B., Smith, T.J., Davis, P.J. and Blas, S.D.: Displacement by retinoic acid of radiolabeled T₄ and T₃ from binding sites on human erythrocyte membranes. **Endocrinology Supplement** 124:288, 1989.

27. Warren, J.T., Jr., Kline, E.L. and Smith, T.J.: Modulation of tyrosinase RNA levels in B16 melanoma cell culture by imidazole, testosterone and triiodothyronine. **Program of the meeting of the American Society of Microbiology**, New Orleans, LA, May 1989.
28. Davis, P.J., Smith, T.J., Davis, F.B., Schoenl, M., Cody, V. and Luft, J.: Human transthyretin (TBPA) binds retinoic acid, but not retinol, at the thyroid hormone-binding site. **Program of the meeting of the American Thyroid Association**, September, 1989.
29. Spaulding, S.W., Smith, T.J., Hinkle, P.M. and Roth, J.: Evidence that the thyromimetic response to triiodothyronine sulfate in human dermal fibroblasts involves desulfation. **Program of the meeting of the American Thyroid Association**, September 1989.
30. Mulloy, A.L., Smith, T.J., Stachura, M.E.: Growth hormone synthesis and release following treatment of hypothyroid rats with thyroxine and/or retinoic acid. **Clinical Research** 38:8A, 1990.
31. Mulloy, A.L., Smith, T.J. and Stachura, M.E.: Growth hormone synthesis and release following treatment of hypothyroid rats with thyroxine and/or retinoic acid. **Clinical Research** 38:343A, 1990.
32. Deziel, M.R., Smith, T.J., Davis, F.B. and Davis, P.J.: Retinoic acid is a calmodulin inhibitor in the human erythrocyte membrane. **Clinical Research** 38:436A, 1990.
33. Shah, S., Lau, K.M., Smith, T.J., Lau, J.T.Y. and Lance, P.: Sodium butyrate reduces mRNA expression of a putative human sialyltransferase in HEP G2 cells. **Program of the American Gastroenterological Association**, San Antonio, TX, May 13-16, 1990.
34. Korducki, J.M., Loftus, S.J., Ting, A.T., Smith, T.J., Gorman, C.A. and Bahn, R.S.: Interleukin-1 stimulation of [³H]glycosaminoglycan accumulation in retroocular and pretibial fibroblasts: Potential role in the extrathyroidal manifestations of Graves' disease. **Endocrinology Supplement** 126: 1990.
35. Smith, T.J., Davis, F.B., Davis, P.J. and Blas, S.D.: Stereochemical requirements for the use of retinoid blockade of thyroid hormone binding and activation of Ca²⁺-ATPase in human erythrocyte membranes. **Program of the 10th International Thyroid Congress**, Jerusalem, Israel, September 9-14, 1990.
36. Kundu, P., Schwartz, N.B. and Smith, T.J.: Thyroid hormone stimulation of hyaluronate synthetase activity in cultured chick chondrocytes. **Program of the annual meeting of the Society for Complex Carbohydrates**, San Diego, CA, October 10-13, 1990.
37. Ucar, K. and Smith, T.J.: H₂ antagonists stimulate melanogenesis in cultured B16 melanoma cells. **Clinical Research** 39:279A, 1991.

38. Davis, F.B., Davis, P.J., Smith, T.J. and Blas, S.D.: Structure-activity relationships of retinoids as inhibitors of calmodulin binding and action at the erythrocyte membrane. **Endocrinology Supplement**.
39. Smith, T.J., Ahmed A., Hogg, M.G. and Higgins, P.J.: Plasminogen Activator Inhibitor Type-1 (PAI-1) Induction by Interferon Gamma in Human Orbital Fibroblast Cultures. **Program of The American Society for Biochemistry and Molecular Biology**, Houston, TX, 1992.
40. Smith, T.J.: Glycosaminoglycans (GAG) and extracellular matrix (ECM) proteins accumulating in orbital fibroblast cultures. Plenary Session. 66th Annual meeting, American Thyroid Association, Rochester, MN 23-26 September, 1992 **Thyroid** 2:S5, 1992.
41. Smith, T.J., Corasanti, J.G., Andersen, V. and Lance, P.: Regulation of plasminogen activator inhibitor type-1 (PAI-1) by n-butyrate (nB) in HEP G2 cells in culture. **Program of the American Society for Biochemistry and Molecular Biology**, San Diego, CA, 1993.
42. Hogg, M.G., Wang, H.S., Evans, C.R. and Smith, T.J.: Leukoregulin (LR), is a potent inducer of plasminogen activator inhibitor-type 1 (PAI-1) and hyaluronate (HA) synthesis in cultured orbital fibroblasts. **Thyroid** 3:T-81, 1993.
43. Smith, T.J.: PGE₂ induces morphological changes in cultured orbital fibroblasts from patients with Graves' ophthalmopathy. **Program of the 9th International Conference on Prostaglandins and Related Compounds**. Florence, Italy, 6-10 June, 1994.
44. Wang, H.-S., Hogg, M.G. and Smith, T.J.: Prostaglandin E₂-mediated shape changes in orbital fibroblasts from patients with Graves' ophthalmopathy. **Thyroid** 4:S-38, 1994.
45. Wang, H.-S., Hogg, M.G., Winn, V.D., Young, D.A., Evans, C.H. and Smith, T.J.: Leukoregulin induces in human orbital fibroblasts a shape change through an enhancement of PGE₂ production. **Program of the Thirty-fourth annual Meeting of the American Society for Cell Biology**, San Francisco, CA, 1994.
46. Young, D.A., Evans, C.H. and Smith, T.J.: Leukoregulin (Lr) induced changes in cell gene expression specific for orbital and pretibial fibroblasts define phenotypic differences of potential relevance to Graves' disease. **Program of the 11th International Thyroid Congress**, Toronto, Canada, 1995.
47. Wang, H.-S., Winn, V.D., Evans, C.H., Young, D.A. and Smith, T.J.: Anatomic site-selective induction of cyclooxygenase-2 and PGE₂ in human orbital fibroblasts. **Program of the 11th International Thyroid Congress** (plenary oral presentation), Toronto, Canada, 1995.

48. Smith, T.J.: Orbital connective tissue: An overview (Plenary session). **Progress in Thyroid Associated Ophthalmopathy**. A satellite to the 11th International Thyroid Congress. Pittsburgh, PA, 8-9 September, 1995
49. Kaback, L.A. and Smith, T.J.: Expression and regulation of hyaluronan synthase (HS) mRNAs in primary human fibroblasts: Potential insights into diseases of the thyroid. **Program of the American Thyroid Association**, Colorado Springs, CO, Oct. 15-19, 1997. S-10
50. Cao, H.J. and Smith, T.J.: Leukoregulin (LR) and IL-1 induce prostaglandin-endoperoxide H synthase-2 (PGHS-2) expression in human orbital fibroblasts: Evidence for fibroblast type-selective cytokine actions. **Program of the American Thyroid Association**, Colorado Springs, CO, Oct. 15-19, 1997. S-42
51. Cao, H.J., Sciaky, D. and Smith, T.J.: Constitutive expression of prostaglandin-endoperoxide H synthase-2 (PGHS-2) in the human thyroid cell line KAT-50. **81st Annual Meeting of the Endocrine Society**, San Diego, CA, June, 1999.
52. Sorisky, A., Bell, A., Grunder, L., Gagnon, A.M., Parikh, S.J. and Smith, T.J.: Functional TSH receptor expression in cultured human preadipocytes. **Program of the American Thyroid Association**, Palm Beach, FL, Sept., 1999.
53. Han, R., Smith, T.J.: IL-1 β induces tissue inhibitor of metalloprotease type 1 (TIMP-1) production in orbital fibroblasts. **Program of the Experimental Biology Meeting (oral presentation)**, San Diego, CA, April 2003.
54. Chen, B., Tsui, S., Smith, T.J.: IL-4 induces 15-lipoxygenase expression in orbital fibroblasts from patients with thyroid-associated ophthalmopathy. **Program of the Experimental Biology Meeting**, San Diego, CA, April 2003.
55. Tsui, S., Smith, T.J.: Characterization of human UDP-glucose dehydrogenase promoter. **Program of the Experimental Biology Meeting**, San Diego, CA, April 2003.
56. Gianoukakis A.G., Tsui S., Hoa H., Hikim A.S., Smith T.J.: Evidence for an association between TSH and IGF-1 receptors in human thyrocytes and fibroblasts. **American Thyroid Association, 76th annual meeting**, Vancouver, Canada, September 29- October 3, 2004. Abstract # 15
57. Gilbert J.A., Gianoukakis A.G., Salehi S., Moorehead J., Khan Z., McGregor A.M., Smith T.J., Banga J.P.: Monoclonal pathogenic antibodies to the TSH receptor of Graves' disease with potent thyroid stimulating activity, but differential blocking activity activate multiple signaling pathways. **13th International Thyroid Congress**, Buenos Aires, Argentina, October 30- November 4, 2005.

58. Gianoukakis A.G., Cruikshank W.W., Smith T.J.: IgG from patients with Graves' disease induce IL-16 and RANTES expression in cultured human thyrocytes: A putative mechanism for T cell infiltration of the thyroid in autoimmune disease. **13th International Thyroid Congress**, Buenos Aires, Argentina, October 30-November 4, 2005.
59. Douglas R., Goldberg R., Smith T.: Phenotypic analysis of disease activity in the peripheral immune system of Graves' disease. **13th International Thyroid Congress**, Buenos Aires, Argentina, October 30- November 4, 2005.
60. Han R., Smith T.J.: IL-1 induces lower sIL-1ra and higher icIL-1ra IL-1ra protein expression in orbital vs. dermal fibroblasts. **American Society for Biochemistry and Molecular Biology (ASBMB)**, San Francisco, CA, April 2006. FASEB J. 20:A640-A641, 2006.

CASE REPORTS

None.